therapeutic effect of glucocorticoid inhalation for pulmonary fibrosis in ards patients
Clicks: 322
ID: 202352
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
322 views
34 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #29 of 124 articles by views in frontiers in neurorobotics
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 124 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objective To observe the effect of glucocorticoid inhalation on the clinical symptoms and pulmonary fibrosis index in ARDS patients. Methods Fifty-three ARDS patients admitted to ICU of Songjiang District Center Hospital of Shanghai from Dec. 2011 to Jun. 2013 were randomly divided into two groups. Group A (n=29) received conventional therapy, and group B (n=24) was given glucocorticoid inhalation treatment (budesonide, 2 mg, 1/12 h, for 12 days) on the basis of the conventional therapy. The oxygenation index, time of extubation, changes in pulmonary fibrosis index, including collagen Ⅰ(Co Ⅰ), Ⅲ procollagen peptide (PⅢP) and transforming growth factor (TGF-β1) were compared between the two groups, and the incidence of common adverse reactions were analyzed. Results The oxygenation index of patients in group B was significantly improved on the 15th day compared with group A (P<0.05). There was a significant difference in the level of Co I, PⅢP and TGF-β1 between two groups as measured with enzyme-linked immunosorbent assay (P<0.05). The hormone therapy did not increase adverse effects (P>0.05). Conclusion A small dose of glucocorticoids introduced by inhalation can improve the oxygenation index and pulmonary fibrosis level without increasing common adverse reactions, suggesting that the inhalation of corticosteroid may be a clinically safe and effective way in patients with ARDS.
DOI: 10.11855/j.issn.0577-7402.2014.09.13
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (129 words).
Try re-searching for a better abstract.
| Reference Key |
zhao2014medicaltherapeutic
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Wen-biao ZHAO;Sheng-xia WAN;De-fang GU;Bin SHI |
| Journal | frontiers in neurorobotics |
| Year | 2014 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.